药物基因组学检测的临床与监管考量
本文综述了药物基因组学检测信息纳入药品说明书的典型案例,探讨现有证据、公共卫生影响和预测效用如何影响临床采纳。监管科学与临床实践均依赖数据驱动决策,但成本等额外因素导致检测临床 uptake 异质性。
要点
- FDA 积极将药物基因组学信息纳入新药和已上市药品说明书。
- 部分检测已转化为常规实践,但许多药物的基因检测临床采纳有限。
- 临床实践受成本等非监管因素影响,导致检测采纳异质性。
核心结论
- 监管科学与临床实践均依赖数据驱动决策,但临床实践中额外因素不影响监管决策,可能导致药物基因组学检测临床采纳的异质性。
研究设计与样本
- 本文为综述,重新审视了药物基因组学检测信息被添加到药品说明书的值得注意的例子。
主要发现
- 药物基因组学进展带来了关于药物反应变异遗传基础的新发现。
- FDA 认识到药物基因组学检测策略的价值,并积极将药物基因组学信息纳入新药和已上市药品的说明书。
- 一些例子已 readily translated to routine clinical practice,但许多药物的基因检测临床 uptake 有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Both regulatory science and clinical practice rely on best available scientific data to guide decision-making. However, changes in clinical practice may be driven by numerous other factors such as cost. In this review, we reexamine noteworthy examples where pharmacogenetic testing information was added to drug labeling to explore how the available evidence, potential public health impact, and predictive utility of each pharmacogenetic biomarker impacts clinical uptake. SUMMARY: Advances in the field of pharmacogenetics have led to new discoveries about the genetic basis for variability in drug response. The Food and Drug Administration recognizes the value of pharmacogenetic testing strategies and has been proactive about incorporating pharmacogenetic information into the labeling of both new drugs and drugs already on the market. Although some examples have readily translated to routine clinical practice, clinical uptake of genetic testing for many drugs has been limited. CONCLUSION: Both regulatory science and clinical practice rely on data-driven approaches to guide decision making; however, additional factors are also important in clinical practice that do not impact regulatory decision making, and these considerations may result in heterogeneity in clinical uptake of pharmacogenetic testing.
引用
- Schuck RN, Marek E, Rogers H, et al. Clinical and regulatory considerations in pharmacogenetic testing. Am J Health Syst Pharm. 2016. PMID: 27864207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。